非编码 RNA 作为肾纤维化治疗靶点的新探索。

EA 4483-IMPECS-IMPact of Environmental ChemicalS on Human Health, Univ. Lille, 59045 Lille CEDEX, France.

Département de la Recherche en Santé, CHU Lille, 59037 Lille, France.

Int J Mol Sci. 2019 Apr 23;20(8):1977. doi: 10.3390/ijms20081977.

Fibrosis, or tissue scarring, is defined as the excessive, persistent and destructive accumulation of extracellular matrix components in response to chronic tissue injury. Renal fibrosis represents the final stage of most chronic kidney diseases and contributes to the progressive and irreversible decline in kidney function. Limited therapeutic options are available and the molecular mechanisms governing the renal fibrosis process are complex and remain poorly understood. Recently, the role of non-coding RNAs, and in particular microRNAs (miRNAs), has been described in kidney fibrosis. Seminal studies have highlighted their potential importance as new therapeutic targets and innovative diagnostic and/or prognostic biomarkers. This review will summarize recent scientific advances and will discuss potential clinical applications as well as future research directions.

纤维化，或组织瘢痕形成，定义为对慢性组织损伤的过度、持续和破坏性细胞外基质成分的积累。肾脏纤维化是大多数慢性肾脏病的终末期，并导致肾功能进行性和不可逆转的下降。目前可用的治疗选择有限，而调控肾脏纤维化过程的分子机制复杂且仍知之甚少。最近，非编码 RNA，特别是 microRNAs (miRNAs)，在肾脏纤维化中的作用已被描述。开创性的研究强调了它们作为新的治疗靶点以及创新的诊断和/或预后生物标志物的潜在重要性。这篇综述将总结最近的科学进展，并讨论潜在的临床应用和未来的研究方向。